Parkinson's Disease
July 2019 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Parkinson's Disease abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Parkinson's Disease. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Parkinson's Disease. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Parkinson's Disease every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Parkinson's disease: Mechanisms, translational models and management strategies.
Authors:Raza C, Anjum R, Shakeel NUA
Institution:Department of Zoology, Government College University, Lahore 54000, Pakistan. Electronic address: chandraza@gcu.edu.pk.
Journal:Life Sci. 2019 Jun 1;226:77-90. doi: 10.1016/j.lfs.2019.03.057. Epub 2019 Apr 10.

2:Nanodelivery of therapeutic agents in Parkinson's disease.
Authors:Lafuente JV, Requejo C, Ugedo L
Institution:LaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Spain. Electronic address: josevicente.lafuente@ehu.eus. at Mount Sinai, New York, NY, United States. Spain.
Journal:Prog Brain Res. 2019;245:263-279. doi: 10.1016/bs.pbr.2019.03.004. Epub 2019 Apr 2.

3:Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease.
Authors:Ozkizilcik A, Sharma A, Lafuente JV, Muresanu DF, Castellani RJ, Nozari A, Tian ZR, Mossler H, Sharma HS
Institution:Department of Biomedical Engineering, University of Arkansas, Fayetteville, AR, United States. Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden. Leioa, Spain. Cluj-Napoca, Romania; "RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania. United States. United States. Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden. Electronic address: sharma@surgsci.uu.se.
Journal:Prog Brain Res. 2019;245:201-246. doi: 10.1016/bs.pbr.2019.03.014. Epub 2019 Apr 2.

4:Parkinson's Disease Dementia and Lewy Body Disease.
Authors:Sezgin M, Bilgic B, Tinaz S, Emre M
Institution:Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Istanbul, Turkey. New Haven, Connecticut. Istanbul, Turkey.
Journal:Semin Neurol. 2019 Apr;39(2):274-282. doi: 10.1055/s-0039-1678579. Epub 2019 Mar 29.

5:Benefits of Vitamins in the Treatment of Parkinson's Disease.
Authors:Zhao X, Zhang M, Li C, Jiang X, Su Y, Zhang Y
Institution:Department of Neurology and Neuroscience Center, First Hospital of Jilin University, Xinmin Street No. 71, Changchun 130000, China. 126 Xin Min Street, Changchun, Jilin 130021, China. Qingdao University, Qingdao, Shandong 266000, China. University, Xinmin Street No. 71, Changchun 130000, China. University, Xinmin Street No. 71, Changchun 130000, China.
Journal:Oxid Med Cell Longev. 2019 Feb 20;2019:9426867. doi: 10.1155/2019/9426867. eCollection 2019.

6:Deep Brain Stimulation for Parkinson Disease.
Authors:Kogan M, McGuire M, Riley J
Institution:Department of Neurosurgery, University at Buffalo, 100 High Street Section B, 4th Floor, Buffalo, NY 14203, USA. University at Buffalo, 875 Ellicott Street, 6071 CTRC, Buffalo, NY 14203, USA. University at Buffalo, Functional Neurosurgery Kaleida Health System, 5959 Big Tree Road, Orchard Park, NY 14207, USA. Electronic address: jriley@ubns.com.
Journal:Neurosurg Clin N Am. 2019 Apr;30(2):137-146. doi: 10.1016/j.nec.2019.01.001.

7:Effect of statins on Parkinson's disease: A systematic review and meta-analysis.
Authors:Yan J, Qiao L, Tian J, Liu A, Wu J, Huang J, Shen M, Lai X
Institution:Laboratory of Molecular Neurobiology.; Department of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, PR China.
Journal:Medicine (Baltimore). 2019 Mar;98(12):e14852. doi: 10.1097/MD.0000000000014852.

8:Association between Sleep Disturbances and Daytime Somnolence in Parkinson's Disease.
Authors:Phattanarudee S, Sangthong S, Bhidayasiri R
Institution:Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand, siripan.p@pharm.chula.ac.th. Chulalongkorn University, Bangkok, Thailand. Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Journal:Eur Neurol. 2018;80(5-6):268-276. doi: 10.1159/000496937. Epub 2019 Feb 7.

9:Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
Authors:Crippa JAS, Hallak JEC, Zuardi AW, Guimaraes FS, Tumas V, Dos Santos RG
Institution:Department of Neurosciences and Behavior, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil. jcrippa@fmrp.usp.br.; National Institute of Science and Technology-Translational Medicine, Ribeirao Preto, Brazil. jcrippa@fmrp.usp.br.; Hospital das Clinicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirao Preto, Sao Paulo, CEP-14049-900, Brazil. jcrippa@fmrp.usp.br.; Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil.
Journal:Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):121-133. doi: 10.1007/s00406-019-00982-6. Epub 2019 Jan 31.

10:Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Authors:Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, van Laar T, Tissingh G, Munts AG, Deuschl G, Lang AE, Dijkgraaf MGW, de Haan RJ, de Bie RMA
Institution:From the Department of Neurology, Amsterdam Neuroscience (C.V.M.V., S.R.S., J.A.B., R.M.A.B.), Clinical Epidemiology, Biostatistics, and Bioinformatics (M.G.W.D.), and the Clinical Research Unit (R.J.H.), Amsterdam UMC, University of Amsterdam, AMC, Amsterdam, the Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Nijmegen (B.P., B.R.B.), the Department of Neurology, Leiden University Medical Center, Leiden (J.J.H.), the Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen (T.L.), the Department of Neurology, Zuyderland Medical Center, Heerlen (G.T.), and the Department of Neurology, Spaarne Gasthuis, Haarlem (A.G.M.) - all in the Netherlands; the Department of Neurology, University Medical Center Schleswig-Holstein, Kiel, Germany (G.D.); and the Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University of Toronto, Toronto (A.E.L.).
Journal:N Engl J Med. 2019 Jan 24;380(4):315-324. doi: 10.1056/NEJMoa1809983.

11:The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis.
Authors:Zhou Z, Zhou R, Zhang Z, Li K
Institution:Department of Epidemiology and Biostatistics, Sichuan University West China School of Public Health, Chengdu, Sichuan, China (mainland). (mainland). Medicine, Shanghai, China (mainland). Shanghai, China (mainland).
Journal:Med Sci Monit. 2019 Jan 23;25:666-674. doi: 10.12659/MSM.912840.

12:Subjective cognitive decline and progression to dementia in Parkinson's disease: a long-term follow-up study.
Authors:Galtier I, Nieto A, Lorenzo JN, Barroso J
Institution:School of Psychology, University of La Laguna, 38205, La Laguna, Tenerife, Spain. igaltier@ull.edu.es. Laguna, Tenerife, Spain.
Journal:J Neurol. 2019 Mar;266(3):745-754. doi: 10.1007/s00415-019-09197-0. Epub 2019 Jan 11.

13:Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.
Authors:Latt MD, Lewis S, Zekry O, Fung VSC
Institution:Geriatric Medicine Department, University of Sydney, Royal Prince Alfred Hospital, KGV Level 7, Missenden Road, Camperdown, NSW, 2050, Australia. mark.latt@sydney.edu.au. Sydney, NSW, Australia. Sydney, NSW, Australia. Australia.
Journal:Drugs Aging. 2019 Mar;36(3):189-202. doi: 10.1007/s40266-018-0629-0.

14:Continuous subcutaneous apomorphine in advanced Parkinson's disease patients treated with deep brain stimulation.
Authors:Sesar A, Fernandez-Pajarin G, Ares B, Relova JL, Aran E, Rivas MT, Gelabert-Gonzalez M, Castro A
Institution:Servicio de Neurologia, Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela, Spain. angel.sesar.ignacio@sergas.es. Santiago de Compostela, Spain. Santiago de Compostela, Spain. Compostela, Santiago de Compostela, Spain. Santiago de Compostela, Spain. Santiago de Compostela, Spain. Santiago de Compostela, Spain. Santiago de Compostela, Spain.
Journal:J Neurol. 2019 Mar;266(3):659-666. doi: 10.1007/s00415-019-09184-5. Epub 2019 Jan 7.

15:Can pimavanserin help patients with Parkinson disease psychosis?
Authors:de la Cruz J, Canal C
Institution:At Mercer University in Atlanta, Ga., Jennifer de la Cruz is a clinical assistant professor in the PA program and Clinton Canal is an assistant professor in the College of Pharmacy's Department of Pharmaceutical Sciences. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Journal:JAAPA. 2019 Jan;32(1):44-45. doi: 10.1097/01.JAA.0000547757.46299.3d.

16:Parkinson's Disease in the Era of Personalised Medicine: One Size Does Not Fit All.
Authors:Ryden LE, Lewis SJG
Institution:Parkinson's Disease Research Clinic, Brain and Mind Centre, University of Sydney, 100 Mallett St, Camperdown, NSW, 2050, Australia. simon.lewis@sydney.edu.au.
Journal:Drugs Aging. 2019 Feb;36(2):103-113. doi: 10.1007/s40266-018-0624-5.

17:Current Drugs and Potential Future Neuroprotective Compounds for Parkinson's Disease.
Authors:Carrera I, Cacabelos R
Institution:Department of Health Biotechnology, EuroEspes Biotechnology, Corunna 15165, Spain. Medicine, Corunna 15166, Spain.
Journal:Curr Neuropharmacol. 2019;17(3):295-306. doi: 10.2174/1570159X17666181127125704.

18:Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.
Authors:Dragasevic-Miskovic N, Petrovic I, Stankovic I, Kostic VS
Institution:a Neurology Clinic, CCS, School of Medicine , Universtiy of Belgrade , Belgrade , Serbia. Serbia. Serbia. Serbia.
Journal:Expert Opin Pharmacother. 2019 Feb;20(2):219-230. doi: 10.1080/14656566.2018.1543407. Epub 2018 Nov 9.

19:Factors associated with freezing of gait in patients with Parkinson's disease.
Authors:Choi SM, Jung HJ, Yoon GJ, Kim BC
Institution:Department of Neurology, Chonnam National University Hospital, Gwangju, South Korea. Baekseo-ro, Dong-gu, Gwangju, 61469, South Korea. Korea. Korea.
Journal:Neurol Sci. 2019 Feb;40(2):293-298. doi: 10.1007/s10072-018-3625-6. Epub 2018 Nov 1.

20:Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
Authors:Bianchi MLE, Riboldazzi G, Mauri M, Versino M
Institution:Centro Parkinson e Disordini del Movimento ASST-SETTELAGHI, Varese, Italy. mlebianchi@hotmail.com. Borghi, Brebbia, Varese, Italy.
Journal:Neurol Sci. 2019 Feb;40(2):275-279. doi: 10.1007/s10072-018-3628-3. Epub 2018 Oct 31.

21:Pharmacogenetics and levodopa induced motor complications.
Authors:Kalinderi K, Papaliagkas V, Fidani L
Institution:a Department of General Biology , Medical School Aristotle University of Thessaloniki , Thessaloniki , Greece. AHEPA University Hospital , Thessaloniki , Greece. Thessaloniki , Thessaloniki , Greece.
Journal:Int J Neurosci. 2019 Apr;129(4):384-392. doi: 10.1080/00207454.2018.1538993. Epub 2018 Dec 2.

22:Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis.
Authors:Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P
Institution:Center for Neurodegenerative Science, Van Andel Research Institute, 333 Bostwick Avenue, NE, Grand Rapids, MI 49503, USA; These authors contributed equally to this work. work. Avenue, NE, Grand Rapids, MI 49503, USA. Avenue, NE, Grand Rapids, MI 49503, USA. Avenue, NE, Grand Rapids, MI 49503, USA. Electronic address: Patrik.Brundin@vai.org.
Journal:Trends Neurosci. 2019 Jan;42(1):4-13. doi: 10.1016/j.tins.2018.09.007. Epub 2018 Oct 17.

23:Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects.
Authors:Vizcarra JA, Situ-Kcomt M, Artusi CA, Duker AP, Lopiano L, Okun MS, Espay AJ, Merola A
Institution:Department of Neurology, Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, 260 Stetson St, Suite 2300, Cincinnati, OH, 45267-0525, USA. Cherasco 15, 10126, Turin, Italy. Movement Disorders, University of Cincinnati, 260 Stetson St, Suite 2300, Cincinnati, OH, 45267-0525, USA. Cherasco 15, 10126, Turin, Italy. McKnight Brain Institute, Gainesville, FL, USA. Movement Disorders, University of Cincinnati, 260 Stetson St, Suite 2300, Cincinnati, OH, 45267-0525, USA.
Journal:J Neurol. 2019 Feb;266(2):289-297. doi: 10.1007/s00415-018-8936-2. Epub 2018 Jun 16.

For a FREE PREVIEW of the Medifocus Guidebook on Parkinson's Disease click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Parkinson's Disease click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Parkinson's Disease...
at a Special 20% Discount


Medifocus Guidebook on Parkinson's Disease

Updated: July 5, 2019
218 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Parkinson's Disease is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

PD93456247

Coupon Expires: September 19, 2019



What Our Customers Are Saying...

"I ordered the MediFocus Guidebook on Parkinson's Disease for my father who has had this condition for about 15 years. It was extremely useful to learn about the medications that are used to treat Parkinson's as well as the side-effects. I had read a lot of articles about Parkinson's on the Internet but they were all very general and vague. Your Guidebook provided excellent and comprehensive information from the medical perspective. Thanks for a very useful resource that is much needed today on the Web."
M.L.
Russelsheim, Germany


"I found your Guidebook on Parkinson's to be very informative for me, the patient, and for my husband. I am in the process of changing my medication and the book explained more to me than the doctor attempted to. I am now more aware of what to expect. It also offered valuable advice for the caregiver. Thank you."
M.N.
Palm Spring, California


"The Medifocus Guide to Parkinson's Disease was useful, informative, and allowed me to grasp the current fundamentals of treatment. I have recommended it to two of my ex-patients whom I know will find it readable and helpful to their needs."
G.B.
Research Triangle Park, NC



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2019 Medifocus, Inc. All rights reserved.